NCT04571203View on ClinicalTrials.gov

Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2029

Conditions
Immune Tolerance
Interventions
BIOLOGICAL

Combined Deceased Donor Kidney and Hematopoietic Cell Transplants

This combined kidney and hematopoietic cell transplants with a conditioning regimen with irradiation and ATG creates an environment of immune-tolerance. This promotes hematopoietic cell engraftment.

Trial Locations (1)

94305

Stanford University, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER